Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of dabrafenib + trametinib in pediatric BRAF V600-mutant low-grade or high-grade glioma
MOH_2022-04-03_007201Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in glioma (3 cohorts), sponsored by Novartis. Primary endpoints: Overall response rate in the high-grade glioma cohort and Overall response rate comparison in the low-grade glioma cohort. Started Dec 2020; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
glioma
Beyond the preview
Go deeper on MOH_2022-04-03_007201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-03_007201.